Small Cap Stocks At 52-Week Highs: Friday’s Full List
A small group of stocks is hitting new highs, with a heavy concentration in one part of the market.
The strongest one-month run on today’s list belongs to Iovance Biotherapeutics (IOVA), up 28.3% while the S&P 500 has returned -0.6%. As of Friday, September 18, there are 10 Small Cap US and Canada-listed stocks in the Trefis coverage universe trading at their 52-week highs. By sector, the 10 names break down as Health Care (6 names), Energy (2 names), Industrials (2 names). The question is whether the underlying business results support these prices.
Friday’s Full 52-Week-High List
Here are all 10 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| HNGE | $7.49 Bil | 0.2% | 7.1% | 7.3% | 67.3% |
| ACA | $7.16 Bil | 0.3% | 0.6% | 0.4% | 56.1% |
| INSW | $5.5 Bil | 0.6% | 7.2% | 17.1% | 164.3% |
| IOVA | $4.61 Bil | 2.3% | 19.2% | 28.3% | 361.7% |
| ADPT | $4.57 Bil | 0.2% | 18.2% | 12.2% | 123.2% |
| HTFL | $4.38 Bil | 2.4% | 1.7% | 11.5% | 59.8% |
| DHT | $3.75 Bil | 2.0% | 5.8% | 16.4% | 106.4% |
| NEOG | $2.83 Bil | 1.3% | 10.4% | 7.0% | 138.1% |
| NEO | $2.58 Bil | 0.1% | 15.0% | 19.5% | 145.5% |
| TH | $2.12 Bil | 2.1% | 10.1% | 24.4% | 146.4% |
This screen covers US and Canada-listed stocks in the Trefis coverage universe. Small Cap here means a market value between $2 billion and $10 billion, the upper figure excluded.
Which names show the fundamentals to match the price?
The list contains very different profiles of business performance. International Seaways (INSW) trades at 7.1 times trailing earnings, and its revenue grew 57.4% over the last twelve months, and its operating margin was 55.7%.
A different picture emerges for Iovance Biotherapeutics (IOVA), which also reached a new high. Its revenue grew 34.5% over the last twelve months, and its operating margin was -91.1%. Both stocks are at their highest price of the past year, but the financial stories are not the same.
How should an investor read this list?
Strength often persists, and a stock reaching a new high can be a sign of a healthy, growing business that the market is rewarding. A high is a price, however, not a verdict.
It marks a point where buyers were willing to pay more than at any time in the past year. The disciplined move is to look past the price and check whether the business itself earns the level. The work begins at the high, it does not end there.
Before chasing any name on this list, ask what the company itself expects next. Our Guidance Momentum screen surfaces the stocks whose managements just raised their own outlooks.
Chasing Highs Is A Reflex. Owning Strength Is A System
A 52-week-high list is seductive: everything on it has been going right. But buying a stock because it is at its high is buying a price, and prices revert; what persists is the quality underneath the run.
The Trefis High Quality (HQ) Portfolio is built to own that quality before and after it makes headlines: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Admire the list; own the system.